Dr Patrick Bowden

Radiation Oncologist
Become a Patient

Dr Patrick Bowden is committed to providing comprehensive, patient-centred cancer care. He is a highly experienced doctor who remains at the forefront of cutting-edge radiation therapy techniques and clinical research.


Dr Patrick Bowden has more than 20 years’ experience as a radiation oncologist, and is committed to providing comprehensive, patient-centred care by remaining at the forefront of innovative radiation therapy practice. He is based at several Icon Cancer Centre sites including Epworth Freemasons, Epworth Richmond, Moreland, Mulgrave and Canberra.

After establishing his radiation oncology career at Peter MacCallum Cancer Centre, he became director of Tattersall’s Cancer Centre in 2007 (the private arm of Peter MacCallum Cancer Centre). In 2011, he was appointed inaugural Director of Epworth Radiation Oncology. In this role he built Australia’s largest stereotactic radiation therapy service including a clinical trial institute and integrated oncology services at Epworth Freemasons. In 2016, the South West Regional Cancer Centre in Warrnambool was established under his directorship, and he played an integral role in the transition of Epworth Radiation Oncology to Icon Cancer Centre.

Dr Bowden is actively involved in education, medical leadership, research and clinical trials. He was previously a member of the Epworth Medical Advisory Committee from 2007-2016 (maximum allowed 9-year tenure). He is also the Chairman of Access Telehealth; Australia’s largest provider of free consultations to patients in rural and remote areas.

Dr Bowden has been active in numerous clinical trials and acted as principal investigator in key studies investigating radiation therapy treatments for lung, cervix and prostate cancers. In July 2019, his world-leading study TRANSFORM was published in the International Journal of Cancer, evaluating the efficacy of stereotactic radiation therapy for oligometastatic prostate cancer. In June 2021, his PINPOINT study investigating the use of Calypso guidance beacons to reduce prostate radiation therapy side effects was published in the World Journal of Urology. Both Australian studies with the support of Epworth Medical Foundation and EJ Whitten Foundation were the world’s largest clinical trials of their kind. With Dr Andrew See, he was co-investigator on PROSPER-82, the largest trial in Australia using spacing gel to protect the rectum during prostate radiotherapy. This study confirmed that spacing gel eliminates severe bowel damage.

His clinical experience covers a broad range of solid tumour malignancies, with a special interest in urological cancers, gastrointestinal cancer and metastatic cancers.


Affiliations & Memberships

  • Royal Australian and New Zealand College of Radiologists (RANZCR)

Special Interests

Dr Patrick Bowden accepts referrals for all cancer types, with a special clinical interest in:
  • Brain and spine (CNS) cancer
  • Gastrointestinal cancer
  • Genitourinary cancer
  • Oligometastatic disease
  • Prostate cancer

Icon Locations

Epworth Richmond View centre
Epworth Freemasons View centre
Moreland View centre
Canberra View centre
Mulgrave View centre
Holmesglen View centre

Visiting Locations

  • Malvern
  • Lilydale
  • Epworth Eastern
  • Box Hill


  • Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial. International Journal of Cancer · Jun 19, 2024

  • Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial. Radiation Oncology · Jul 25, 2022

  • Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. World Journal of Urology · May 30, 2021

  • Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. International Journal of Cancer · Jun 13, 2019

  • Targeted local therapy in oligometastatic prostate cancer: a promising potential opportunity after failed primary treatment. BJU International · Dec 27, 2014

  • Prostate cancer multidisciplinary care: improving patient outcomes. Prostate cancer multidisciplinary care: improving patient outcomes. Trends in Urology & Men’s Health

  • The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews

  • Using PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy. Annals of Oncology